local_hospital

Asklepieion Voulas General Hospital

Address
lock Available on a paid plan

Cardiovascular Diseases

At Asklepieion Voulas General Hospital, the Department of Cardiology is conducting a broad range of studies in cardiovascular diseases, focusing on conditions such as atrial fibrillation, heart failure, hypertension, atherosclerotic cardiovascular disease, and acute myocardial infarction. These trials are designed to assess new treatment options, improve rhythm control, and reduce major cardiovascular events in patients at elevated risk.

  • Testing new therapies to lower cardiovascular risk in high-risk patients and those with established disease
  • Evaluating treatments for heart failure, including forms linked to obesity and reduced or preserved ejection fraction
  • Studying approaches to restore and maintain normal heart rhythm in atrial fibrillation
  • Assessing strategies to reduce complications after myocardial infarction and improve long-term outcomes

This research reflects a strong focus on practical advances in cardiovascular care, from prevention to treatment optimization.

Immune System Diseases

The site is also active in immune system diseases, with studies in Sjögren’s syndrome and systemic lupus erythematosus. These trials aim to better control disease activity, ease patient symptoms, and evaluate whether newer immune-targeted therapies can improve outcomes for people living with chronic autoimmune conditions.

  • Investigating treatments for Sjögren’s syndrome to reduce systemic disease burden and symptom severity
  • Evaluating therapies for systemic lupus erythematosus to help achieve better disease control
  • Exploring immune-modulating approaches that may improve quality of life and clinical stability

These studies highlight an emphasis on refining care for complex autoimmune disorders through targeted therapy.

Infectious Diseases

In the area of infectious diseases, the clinical research includes studies on sepsis and candidemia. The main goal is to test whether immune-based or adjunctive treatments can improve survival, support faster infection control, and reduce the severe complications associated with life-threatening infections.

  • Assessing new treatment strategies for sepsis to improve outcomes in critically ill patients
  • Studying therapies for candidemia to support faster clearance of infection and better recovery
  • Exploring immune-targeted approaches in severe infection management

This work shows a focus on improving care for serious hospital-based infections through more precise treatment approaches.

Analytical, Diagnostic and Therapeutic Techniques and Equipment

The research portfolio also includes analytical, diagnostic and therapeutic techniques and equipment related studies, with an emphasis on improving how cardiovascular and inflammatory diseases are treated and monitored. At Asklepieion Voulas General Hospital, these trials are helping evaluate whether newer approaches can deliver better disease control and clinical benefit in routine care.

  • Developing more effective treatment strategies for complex chronic conditions
  • Supporting better monitoring of disease activity and treatment response
  • Examining innovative options that may improve care delivery in cardiology and immune-mediated disease

This area connects the hospital’s clinical trial activity with efforts to improve both treatment effectiveness and patient management.

Respiratory Tract Diseases

The site’s trial activity also touches on respiratory tract diseases through research in severe systemic illness, where lung-related complications can be part of broader critical care needs. These studies are aimed at improving outcomes in patients with serious infection-driven conditions and reducing the risk of deterioration.

  • Investigating treatment approaches for patients with severe infection-related respiratory complications
  • Supporting better outcomes in critically ill patients with multi-organ involvement
  • Evaluating therapies that may lessen the impact of severe systemic disease on breathing and recovery

This research contributes to broader efforts in acute care medicine, especially where respiratory health is affected by severe illness.

Virus Diseases

Within virus diseases, the clinical trial landscape includes studies that intersect with immune response and infection control. The research is focused on whether targeted treatments can improve outcomes in serious infectious conditions and help the body respond more effectively to disease.

  • Exploring immune-based therapies for infection-related illness
  • Assessing whether new treatment approaches can improve recovery in severe disease
  • Studying the role of targeted intervention in reducing complications from infection

These trials reflect an interest in advancing care for difficult-to-treat infections through more precise therapeutic options.

Eye Diseases

The research profile includes a smaller but notable presence in eye diseases, linked here to broader immune-mediated conditions that can affect multiple organs. The purpose of this work is to better understand disease patterns and evaluate treatments that may help control systemic inflammation.

  • Studying how immune-related disease activity may affect eye health
  • Evaluating therapies that may improve control of multi-system inflammatory disease
  • Supporting research that connects ophthalmic care with broader autoimmune treatment

This area adds to the hospital’s wider effort to improve care across interconnected disease systems.

Site Overview

assignment
18
connected trials
corporate_fare
17
sponsors
science
24
IMPs

Activity Indicator

Last 6 months

4
Trials started
+100% vs previous period.
2
Trials started 6–12 months ago
18
Total trials linked
Highly Active
trending_upGrowing+100%
1
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 7 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
9
Sponsors (total)
17
Active sponsors
9

Sponsor Network

Top 9 by active trials.

lock +8 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 173 other sites in Greece

description
Trial volume
18
Outperforms 75% of sites
public
Therapeutic diversity
8areas
Outperforms 84% of sites
groups
Sponsor diversity
17sponsors
Outperforms 80% of sites

Therapeutic Area Benchmark — Greece

Select a therapeutic area to compare against other sites in Greece.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Greece

Market Share

Country: Greece

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Asklepieion Voulas General Hospital

lock Showing 1 of 18 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2 Study to Evaluate the Efficacy and Safety of Transitioning to KPL-387 Monotherapy in Participants with Well-Controlled Recurrent PericarditisKiniksa Pharmaceuticals GmbHPhase IIRecruitingApr 2026

IMP list

lock Showing 1 of 24 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Abelacimab1Unknown2023-10-312023-10-31

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.